Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review

Mycobacterial infections are considered to a serious challenge of medicine, and the emergence of MDR and XDR tuberculosis is a serious public health problem. Tuberculosis can cause high morbidity and mortality around the world, particularly in developing countries. The emergence of drug-resistant My...

Full description

Saved in:
Bibliographic Details
Published in:Infection and drug resistance 2019-09, Vol.12, p.2943-2959
Main Authors: Azimi, Taher, Mosadegh, Mehrdad, Nasiri, Mohammad Javad, Sabour, Sahar, Karimaei, Samira, Nasser, Ahmad
Format: Article
Language:English
Subjects:
Antibiotics
Antitubercular agents
Bacterial infections
Care and treatment
Control programs
Developing countries
Drug resistance
Epidemics
Health aspects
Infection
Infections
Iran
LDCs
Morbidity
Mycobacteria infection
Mycobacteriophage
Mycobacterium
Novels
Phage therapy
Phages
Public health
Public health movements
Review
Technology
Therapeutic applications
Tuberculosis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c573t-a61e849e42d2846a781e325066196a8466237271be0e5fc8acce65d79ba9282d3
cites
container_end_page 2959
container_issue
container_start_page 2943
container_title Infection and drug resistance
container_volume 12
creator Azimi, Taher
Mosadegh, Mehrdad
Nasiri, Mohammad Javad
Sabour, Sahar
Karimaei, Samira
Nasser, Ahmad
description Mycobacterial infections are considered to a serious challenge of medicine, and the emergence of MDR and XDR tuberculosis is a serious public health problem. Tuberculosis can cause high morbidity and mortality around the world, particularly in developing countries. The emergence of drug-resistant Mycobacterium infection following limited therapeutic technologies coupled with the serious worldwide tuberculosis epidemic has adversely affected control programs, thus necessitating the study of the role bacteriophages in the treatment of mycobacterial infection. Bacteriophages are viruses that are isolated from several ecological specimens and do not exert adverse effects on patients. Phage therapy can be considered as a significant alternative to antibiotics for treating MDR and XDR mycobacterial infections. The useful ability of bacteriophages to kill spp has been explored by numerous research studies that have attempted to investigate the phage therapy as a novel therapeutic/diagnosis approach to mycobacterial infections. However, there are restricted data about phage therapy for treating mycobacterial infections. This review presents comprehensive data about phage therapy in the treatment of mycobacterial infection, specifically tuberculosis disease.
doi_str_mv 10.2147/IDR.S218638
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9cdd619f3c5546fea33cc714c0847b81</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A604315255</galeid><doaj_id>oai_doaj_org_article_9cdd619f3c5546fea33cc714c0847b81</doaj_id><sourcerecordid>A604315255</sourcerecordid><originalsourceid>FETCH-LOGICAL-c573t-a61e849e42d2846a781e325066196a8466237271be0e5fc8acce65d79ba9282d3</originalsourceid><addsrcrecordid>eNptkltr2zAUgM3YWEvXp70Pw2AMRjJLsm57GJTuFihs7PIsTuTjWMG2XMlOyb-fmmRdMiY_yBx_5zPnkmXPSTGnpJRvFx--z39QogRTj7JzQqSaCS3Z46P3s-wyxnWRDtOilPRpdsYIl0SX8jyz3xpYYT42GGDY5hBzyAP2eIfVIYjT6GwOwxA82CYffd5trV-CHTE4aHPX12hH5_v4LuVa3w0BG-yj22AybRzePcue1NBGvDzcF9mvTx9_Xn-Z3Xz9vLi-uplZLtk4A0FQlRpLWlFVCpCKIKO8EIJoASkiKJNUkiUWyGurwFoUvJJ6CZoqWrGLbLH3Vh7WZgiug7A1HpzZBXxYGQipmBaNtlWVtDWznJeiRmDMWklKW6hSLhVJrvd71zAtO6ws9mOA9kR6-qV3jVn5jRGSCy5lErw-CIK_nTCOpnPRYttCj36KhlKtpUhzYwl9-Q-69lPoU6t2FBeF1uovtYJUQOq6T_-191JzJYoyjZRynqj5f6j0VNg563usXYqfJLw6SmgQ2rGJvp12Ez0F3-xBG3yMAeuHZpDC3O-iSbtoDruY6BfH_Xtg_2we-w24zNds</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2299560998</pqid></control><display><type>article</type><title>Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review</title><source>Publicly Available Content Database</source><source>Taylor &amp; Francis Open Access Journals</source><source>PubMed Central</source><creator>Azimi, Taher ; Mosadegh, Mehrdad ; Nasiri, Mohammad Javad ; Sabour, Sahar ; Karimaei, Samira ; Nasser, Ahmad</creator><creatorcontrib>Azimi, Taher ; Mosadegh, Mehrdad ; Nasiri, Mohammad Javad ; Sabour, Sahar ; Karimaei, Samira ; Nasser, Ahmad</creatorcontrib><description>Mycobacterial infections are considered to a serious challenge of medicine, and the emergence of MDR and XDR tuberculosis is a serious public health problem. Tuberculosis can cause high morbidity and mortality around the world, particularly in developing countries. The emergence of drug-resistant Mycobacterium infection following limited therapeutic technologies coupled with the serious worldwide tuberculosis epidemic has adversely affected control programs, thus necessitating the study of the role bacteriophages in the treatment of mycobacterial infection. Bacteriophages are viruses that are isolated from several ecological specimens and do not exert adverse effects on patients. Phage therapy can be considered as a significant alternative to antibiotics for treating MDR and XDR mycobacterial infections. The useful ability of bacteriophages to kill spp has been explored by numerous research studies that have attempted to investigate the phage therapy as a novel therapeutic/diagnosis approach to mycobacterial infections. However, there are restricted data about phage therapy for treating mycobacterial infections. This review presents comprehensive data about phage therapy in the treatment of mycobacterial infection, specifically tuberculosis disease.</description><identifier>ISSN: 1178-6973</identifier><identifier>EISSN: 1178-6973</identifier><identifier>DOI: 10.2147/IDR.S218638</identifier><identifier>PMID: 31571947</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Antibiotics ; Antitubercular agents ; Bacterial infections ; Care and treatment ; Control programs ; Developing countries ; Drug resistance ; Epidemics ; Health aspects ; Infection ; Infections ; Iran ; LDCs ; Morbidity ; Mycobacteria infection ; Mycobacteriophage ; Mycobacterium ; Novels ; Phage therapy ; Phages ; Public health ; Public health movements ; Review ; Technology ; Therapeutic applications ; Tuberculosis</subject><ispartof>Infection and drug resistance, 2019-09, Vol.12, p.2943-2959</ispartof><rights>2019 Azimi et al.</rights><rights>COPYRIGHT 2019 Dove Medical Press Limited</rights><rights>2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 Azimi et al. 2019 Azimi et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c573t-a61e849e42d2846a781e325066196a8466237271be0e5fc8acce65d79ba9282d3</citedby><orcidid>0000-0003-0213-5227 ; 0000-0002-3279-0671</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2299560998/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2299560998?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25732,27903,27904,36991,36992,44569,53769,53771,74872</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31571947$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Azimi, Taher</creatorcontrib><creatorcontrib>Mosadegh, Mehrdad</creatorcontrib><creatorcontrib>Nasiri, Mohammad Javad</creatorcontrib><creatorcontrib>Sabour, Sahar</creatorcontrib><creatorcontrib>Karimaei, Samira</creatorcontrib><creatorcontrib>Nasser, Ahmad</creatorcontrib><title>Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review</title><title>Infection and drug resistance</title><addtitle>Infect Drug Resist</addtitle><description>Mycobacterial infections are considered to a serious challenge of medicine, and the emergence of MDR and XDR tuberculosis is a serious public health problem. Tuberculosis can cause high morbidity and mortality around the world, particularly in developing countries. The emergence of drug-resistant Mycobacterium infection following limited therapeutic technologies coupled with the serious worldwide tuberculosis epidemic has adversely affected control programs, thus necessitating the study of the role bacteriophages in the treatment of mycobacterial infection. Bacteriophages are viruses that are isolated from several ecological specimens and do not exert adverse effects on patients. Phage therapy can be considered as a significant alternative to antibiotics for treating MDR and XDR mycobacterial infections. The useful ability of bacteriophages to kill spp has been explored by numerous research studies that have attempted to investigate the phage therapy as a novel therapeutic/diagnosis approach to mycobacterial infections. However, there are restricted data about phage therapy for treating mycobacterial infections. This review presents comprehensive data about phage therapy in the treatment of mycobacterial infection, specifically tuberculosis disease.</description><subject>Antibiotics</subject><subject>Antitubercular agents</subject><subject>Bacterial infections</subject><subject>Care and treatment</subject><subject>Control programs</subject><subject>Developing countries</subject><subject>Drug resistance</subject><subject>Epidemics</subject><subject>Health aspects</subject><subject>Infection</subject><subject>Infections</subject><subject>Iran</subject><subject>LDCs</subject><subject>Morbidity</subject><subject>Mycobacteria infection</subject><subject>Mycobacteriophage</subject><subject>Mycobacterium</subject><subject>Novels</subject><subject>Phage therapy</subject><subject>Phages</subject><subject>Public health</subject><subject>Public health movements</subject><subject>Review</subject><subject>Technology</subject><subject>Therapeutic applications</subject><subject>Tuberculosis</subject><issn>1178-6973</issn><issn>1178-6973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkltr2zAUgM3YWEvXp70Pw2AMRjJLsm57GJTuFihs7PIsTuTjWMG2XMlOyb-fmmRdMiY_yBx_5zPnkmXPSTGnpJRvFx--z39QogRTj7JzQqSaCS3Z46P3s-wyxnWRDtOilPRpdsYIl0SX8jyz3xpYYT42GGDY5hBzyAP2eIfVIYjT6GwOwxA82CYffd5trV-CHTE4aHPX12hH5_v4LuVa3w0BG-yj22AybRzePcue1NBGvDzcF9mvTx9_Xn-Z3Xz9vLi-uplZLtk4A0FQlRpLWlFVCpCKIKO8EIJoASkiKJNUkiUWyGurwFoUvJJ6CZoqWrGLbLH3Vh7WZgiug7A1HpzZBXxYGQipmBaNtlWVtDWznJeiRmDMWklKW6hSLhVJrvd71zAtO6ws9mOA9kR6-qV3jVn5jRGSCy5lErw-CIK_nTCOpnPRYttCj36KhlKtpUhzYwl9-Q-69lPoU6t2FBeF1uovtYJUQOq6T_-191JzJYoyjZRynqj5f6j0VNg563usXYqfJLw6SmgQ2rGJvp12Ez0F3-xBG3yMAeuHZpDC3O-iSbtoDruY6BfH_Xtg_2we-w24zNds</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Azimi, Taher</creator><creator>Mosadegh, Mehrdad</creator><creator>Nasiri, Mohammad Javad</creator><creator>Sabour, Sahar</creator><creator>Karimaei, Samira</creator><creator>Nasser, Ahmad</creator><general>Dove Medical Press Limited</general><general>Taylor &amp; Francis Ltd</general><general>Dove</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-0213-5227</orcidid><orcidid>https://orcid.org/0000-0002-3279-0671</orcidid></search><sort><creationdate>20190901</creationdate><title>Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review</title><author>Azimi, Taher ; Mosadegh, Mehrdad ; Nasiri, Mohammad Javad ; Sabour, Sahar ; Karimaei, Samira ; Nasser, Ahmad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c573t-a61e849e42d2846a781e325066196a8466237271be0e5fc8acce65d79ba9282d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antibiotics</topic><topic>Antitubercular agents</topic><topic>Bacterial infections</topic><topic>Care and treatment</topic><topic>Control programs</topic><topic>Developing countries</topic><topic>Drug resistance</topic><topic>Epidemics</topic><topic>Health aspects</topic><topic>Infection</topic><topic>Infections</topic><topic>Iran</topic><topic>LDCs</topic><topic>Morbidity</topic><topic>Mycobacteria infection</topic><topic>Mycobacteriophage</topic><topic>Mycobacterium</topic><topic>Novels</topic><topic>Phage therapy</topic><topic>Phages</topic><topic>Public health</topic><topic>Public health movements</topic><topic>Review</topic><topic>Technology</topic><topic>Therapeutic applications</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Azimi, Taher</creatorcontrib><creatorcontrib>Mosadegh, Mehrdad</creatorcontrib><creatorcontrib>Nasiri, Mohammad Javad</creatorcontrib><creatorcontrib>Sabour, Sahar</creatorcontrib><creatorcontrib>Karimaei, Samira</creatorcontrib><creatorcontrib>Nasser, Ahmad</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Infection and drug resistance</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Azimi, Taher</au><au>Mosadegh, Mehrdad</au><au>Nasiri, Mohammad Javad</au><au>Sabour, Sahar</au><au>Karimaei, Samira</au><au>Nasser, Ahmad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review</atitle><jtitle>Infection and drug resistance</jtitle><addtitle>Infect Drug Resist</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>12</volume><spage>2943</spage><epage>2959</epage><pages>2943-2959</pages><issn>1178-6973</issn><eissn>1178-6973</eissn><abstract>Mycobacterial infections are considered to a serious challenge of medicine, and the emergence of MDR and XDR tuberculosis is a serious public health problem. Tuberculosis can cause high morbidity and mortality around the world, particularly in developing countries. The emergence of drug-resistant Mycobacterium infection following limited therapeutic technologies coupled with the serious worldwide tuberculosis epidemic has adversely affected control programs, thus necessitating the study of the role bacteriophages in the treatment of mycobacterial infection. Bacteriophages are viruses that are isolated from several ecological specimens and do not exert adverse effects on patients. Phage therapy can be considered as a significant alternative to antibiotics for treating MDR and XDR mycobacterial infections. The useful ability of bacteriophages to kill spp has been explored by numerous research studies that have attempted to investigate the phage therapy as a novel therapeutic/diagnosis approach to mycobacterial infections. However, there are restricted data about phage therapy for treating mycobacterial infections. This review presents comprehensive data about phage therapy in the treatment of mycobacterial infection, specifically tuberculosis disease.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>31571947</pmid><doi>10.2147/IDR.S218638</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-0213-5227</orcidid><orcidid>https://orcid.org/0000-0002-3279-0671</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-6973
ispartof Infection and drug resistance, 2019-09, Vol.12, p.2943-2959
issn 1178-6973
1178-6973
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_9cdd619f3c5546fea33cc714c0847b81
source Publicly Available Content Database; Taylor & Francis Open Access Journals; PubMed Central
subjects Antibiotics
Antitubercular agents
Bacterial infections
Care and treatment
Control programs
Developing countries
Drug resistance
Epidemics
Health aspects
Infection
Infections
Iran
LDCs
Morbidity
Mycobacteria infection
Mycobacteriophage
Mycobacterium
Novels
Phage therapy
Phages
Public health
Public health movements
Review
Technology
Therapeutic applications
Tuberculosis
title Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T21%3A31%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phage%20therapy%20as%20a%20renewed%20therapeutic%20approach%20to%20mycobacterial%20infections:%20a%20comprehensive%20review&rft.jtitle=Infection%20and%20drug%20resistance&rft.au=Azimi,%20Taher&rft.date=2019-09-01&rft.volume=12&rft.spage=2943&rft.epage=2959&rft.pages=2943-2959&rft.issn=1178-6973&rft.eissn=1178-6973&rft_id=info:doi/10.2147/IDR.S218638&rft_dat=%3Cgale_doaj_%3EA604315255%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c573t-a61e849e42d2846a781e325066196a8466237271be0e5fc8acce65d79ba9282d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2299560998&rft_id=info:pmid/31571947&rft_galeid=A604315255&rfr_iscdi=true